Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept trial of IDOR-1117-2520 in moderate to severe chronic plaque psoriasis
2025-523051-64-00Phase 2Completed
- Sponsor
- Idorsia
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis and psoriatic arthritis (PsA) comparing IDOR-1117-2520 with Placebo (2 arms). Primary endpoint: Change in PASI score at Week 12. Started Jan 2026; status: completed.
02
Drugs
IDOR-1117-2520
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2025-523051-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523051-64-00.